Elisabetta Torlone
Research Subjects
Elisabetta Torlone has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Annunziata Lapolla
Department of Medicine, Diabetology and Dietetics Unit, Padova University, Padua, Italy; Member of AMD Scientific Committee, Rome, Italy
3 shared publications- Elena Succurro
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
3 shared publications Camilla Festa
Interassociative Diabetes and Pregnancy Study Group, Italian Association of Diabetologists (AMD), Italian Diabetes Society (SID), Rome, Italy; Italian Medicines Agency (AIFA), Rome, Italy
2 shared publicationsDomenico Mannino
Associazione Medici Diabetologi AMD, Italy
2 shared publications- Gian Carlo Di Renzo
Sechenov University; Center for Prenatal and Reproductive Medicine, University of Perugia
2 shared publications Gloria Formoso
Interassociative Diabetes and Pregnancy Study Group, Italian Association of Diabetologists (AMD), Italian Diabetes Society (SID), Rome, Italy; Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST,ex CeSIMet), G. d'Annunzio University Chieti-Pescara, Italy
2 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (7) , 120
Promoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trial
Background: Sedentary behavior is a major modifiable risk factor for chronic metabolic disorders, particularly type 2 diabetes mellitus (T2DM). Despite recommendations promoting regular physical activity (PA), adherence remains low. DIA/01 is a multidisciplinary study designed to promote healthy lifestyles for the prevention and management of T2DM, supporting healthcare systems. Methods: A total of 123 adults with T2DM diagnosed will be enrolled at the Diabetes Center of the University Hospital of Perugia throughout 2025. Inclusion criteria are age 25–80 years, ability to walk independently, being inactive, and BMI 18.5–40 kg/m2. Exclusion criteria include severe cardiovascular, central nervous system, or musculoskeletal diseases contraindicating PA. Participants will be randomized into three groups: (1) standard care (SC); (2) SC plus theoretical PA counseling (TCPA); and (3) SC plus TCPA plus a 3-month supervised mixed exercise program. The assessment, conducted at baseline and at 6 and 12 months, includes total weekly PA (WPA) time, using IPAQ-SF and actigraphy. Moreover, glycated hemoglobin, sedentary time (ST), functional capacity, body composition, cardiometabolic risk factors, dietary adherence, perceived barriers and willingness to initiate PA, readiness to change, health-related quality of life, and sleep quality will be studied. This study is registered in the Clinical Trials Registry on 13 May 2026, with the identifier NCT07583355. Conclusions: Participants in groups (2) and (3) are expected to show greater improvements in WPA, reductions in ST, and favorable changes in metabolic and functional outcomes compared with SC. This approach may support long-term engagement in regular PA and contribute to improving the clinical management of T2DM.
- 24 June 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (7) , 120
Open AccessPromoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trial
Background: Sedentary behavior is a major modifiable risk factor for chronic metabolic disorders, particularly type 2 diabetes mellitus (T2DM). Despite recommendations promoting regular physical activity (PA), adherence remains low. DIA/01 is a multidisciplinary study designed to promote healthy lifestyles for the prevention and management of T2DM, supporting healthcare systems. Methods: A total of 123 adults with T2DM diagnosed will be enrolled at the Diabetes Center of the University Hospital of Perugia throughout 2025. Inclusion criteria are age 25–80 years, ability to walk independently, being inactive, and BMI 18.5–40 kg/m2. Exclusion criteria include severe cardiovascular, central nervous system, or musculoskeletal diseases contraindicating PA. Participants will be randomized into three groups: (1) standard care (SC); (2) SC plus theoretical PA counseling (TCPA); and (3) SC plus TCPA plus a 3-month supervised mixed exercise program. The assessment, conducted at baseline and at 6 and 12 months, includes total weekly PA (WPA) time, using IPAQ-SF and actigraphy. Moreover, glycated hemoglobin, sedentary time (ST), functional capacity, body composition, cardiometabolic risk factors, dietary adherence, perceived barriers and willingness to initiate PA, readiness to change, health-related quality of life, and sleep quality will be studied. This study is registered in the Clinical Trials Registry on 13 May 2026, with the identifier NCT07583355. Conclusions: Participants in groups (2) and (3) are expected to show greater improvements in WPA, reductions in ST, and favorable changes in metabolic and functional outcomes compared with SC. This approach may support long-term engagement in regular PA and contribute to improving the clinical management of T2DM.
- 27 November 2020
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 30 (12) , 2389-2397
Gestational diabetes: A link between OGTT, maternal-fetal outcomes and maternal glucose tolerance after childbirth
- 27 November 2020
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 30 (12) , 2389-2397
Gestational diabetes: A link between OGTT, maternal-fetal outcomes and maternal glucose tolerance after childbirth
- 26 September 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (5) , e3411
Follow‐up of women with a history of gestational diabetes in Italy: Are we missing an opportunity for primary prevention of type 2 diabetes and cardiovascular disease?
- 26 September 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (5) , e3411
Follow‐up of women with a history of gestational diabetes in Italy: Are we missing an opportunity for primary prevention of type 2 diabetes and cardiovascular disease?
- 1 August 2020
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 166, 108345
Recommendations and management of hyperglycaemia in pregnancy during COVID-19 pandemic in Italy
- 1 August 2020
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 166, 108345
Recommendations and management of hyperglycaemia in pregnancy during COVID-19 pandemic in Italy
- 1 August 2020
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 30 (9) , 1418-1422
Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: Position statement of the Italian Association of Clinical Diabetologists (AMD) and the Italian Diabetes Society (SID), diabetes, and pregnancy study group
- 1 August 2020
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 30 (9) , 1418-1422
Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: Position statement of the Italian Association of Clinical Diabetologists (AMD) and the Italian Diabetes Society (SID), diabetes, and pregnancy study group
- 25 March 2020
- Published by Springer Nature in L'Endocrinologo
- Vol. 21 (2) , 101-107
Nutrizione e nutraceutica in donne con iperglicemia in gravidanza
- 25 March 2020
- Published by Springer Nature in L'Endocrinologo
- Vol. 21 (2) , 101-107
Nutrizione e nutraceutica in donne con iperglicemia in gravidanza
- Open Access
- 28 March 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (4) , 429
Renal Consequences of Gestational Diabetes Mellitus in Term Neonates: A Multidisciplinary Approach to the DOHaD Perspective in the Prevention and Early Recognition of Neonates of GDM Mothers at Risk of Hypertension and Chronic Renal Diseases in Later Life
Fetal exposure to gestational diabetes mellitus (GDM) seems to stimulate a negative impact on the kidneys. Renal volumes and urinary biomarkers of renal function and tubular impairment and injury were evaluated in 30–40-day old newborns of GDM mothers (n = 139) who needed insulin therapy during pregnancy. We found that neonates of mothers who maintained strict control over normoglycemia (n = 65) during pregnancy and fulfilled the other criteria of the GDM management program showed no differences compared to control (n = 55). Conversely, those (n = 74), whose mothers did not maintain glycemic control and were not compliant to the management program, exhibited significantly lower levels of renal volumes and higher activity of N-acetyl-β-d-glucosaminidase and cathepsin B. Differences due to maternal pre-gestational and gestational body mass index (BMI) as well as to maternal weight gain were demonstrated. Our findings indicate that a multidisciplinary approach, which involves an appropriate management of GDM, prevents the negative effects of GDM on the kidneys at 30–40 days of postnatal age, indicating the fundamental role of glycemic control, as well as of an adequate range of maternal weight gain. Total renal volume, cortical volume, and urinary activity of N-acetyl-β-d-glucosaminidase and cathepsin B may be suggested as indicators for the early recognition of GDM neonates at long-term risk of hypertension and kidney disease.
- 28 March 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (4) , 429
Open AccessRenal Consequences of Gestational Diabetes Mellitus in Term Neonates: A Multidisciplinary Approach to the DOHaD Perspective in the Prevention and Early Recognition of Neonates of GDM Mothers at Risk of Hypertension and Chronic Renal Diseases in Later Life
Fetal exposure to gestational diabetes mellitus (GDM) seems to stimulate a negative impact on the kidneys. Renal volumes and urinary biomarkers of renal function and tubular impairment and injury were evaluated in 30–40-day old newborns of GDM mothers (n = 139) who needed insulin therapy during pregnancy. We found that neonates of mothers who maintained strict control over normoglycemia (n = 65) during pregnancy and fulfilled the other criteria of the GDM management program showed no differences compared to control (n = 55). Conversely, those (n = 74), whose mothers did not maintain glycemic control and were not compliant to the management program, exhibited significantly lower levels of renal volumes and higher activity of N-acetyl-β-d-glucosaminidase and cathepsin B. Differences due to maternal pre-gestational and gestational body mass index (BMI) as well as to maternal weight gain were demonstrated. Our findings indicate that a multidisciplinary approach, which involves an appropriate management of GDM, prevents the negative effects of GDM on the kidneys at 30–40 days of postnatal age, indicating the fundamental role of glycemic control, as well as of an adequate range of maternal weight gain. Total renal volume, cortical volume, and urinary activity of N-acetyl-β-d-glucosaminidase and cathepsin B may be suggested as indicators for the early recognition of GDM neonates at long-term risk of hypertension and kidney disease.
- 10 April 2013
- Published by Cambridge University Press (CUP) in Journal of Developmental Origins of Health and Disease
- Vol. 4 (4) , 285-289
Renal echo-3D and microalbuminuria in children of diabetic mothers: a preliminary study
Maternal diabetes has assumed epidemic relevance in recent years and animal studies have provided some evidence that it may cause abnormalities in renal development and a reduction in nephron endowment in the offspring; however, human data are lacking. The renal cortex contains ∼95% of the glomeruli and its volume could be taken as a surrogate measure of glomerular number; based on this assumption, we measured renal cortex volume and in addition, microalbuminuria in a homogeneous sample of 42 children of diabetic (pregestational, n = 13, and gestational, n = 29) mothers, compared with 21 healthy children born of non-diabetic mothers. The offspring of diabetic mothers showed a significant reduction of renal cortex volume and higher albumin excretion compared with controls, possibly attributable to a reduction in the number of nephrons and the difference was statistically significant (P < 0.001). Although further studies on a larger sample are necessary, our preliminary findings suggest that maternal diabetes may affect renal development with sequelae later in life, requiring closer monitoring and follow-up. Furthermore, the importance of strict maternal diabetes management and control must be emphasized.
- 10 April 2013
- Published by Cambridge University Press (CUP) in Journal of Developmental Origins of Health and Disease
- Vol. 4 (4) , 285-289
Renal echo-3D and microalbuminuria in children of diabetic mothers: a preliminary study
Maternal diabetes has assumed epidemic relevance in recent years and animal studies have provided some evidence that it may cause abnormalities in renal development and a reduction in nephron endowment in the offspring; however, human data are lacking. The renal cortex contains ∼95% of the glomeruli and its volume could be taken as a surrogate measure of glomerular number; based on this assumption, we measured renal cortex volume and in addition, microalbuminuria in a homogeneous sample of 42 children of diabetic (pregestational, n = 13, and gestational, n = 29) mothers, compared with 21 healthy children born of non-diabetic mothers. The offspring of diabetic mothers showed a significant reduction of renal cortex volume and higher albumin excretion compared with controls, possibly attributable to a reduction in the number of nephrons and the difference was statistically significant (P < 0.001). Although further studies on a larger sample are necessary, our preliminary findings suggest that maternal diabetes may affect renal development with sequelae later in life, requiring closer monitoring and follow-up. Furthermore, the importance of strict maternal diabetes management and control must be emphasized.
- 16 June 2009
- Published by Springer Nature in Acta Diabetologica
- Vol. 46 (3) , 163-172
Insulin analogs and pregnancy: an update
It is well known that good metabolic control maintained throughout pregnancy reduces maternal and fetal complications in diabetes. Before conception and throughout pregnancy, insulin therapy needs to be optimized and, in this context, the insulin analogs currently available in the market may help to achieve good metabolic control. We therefore review here what is known about the potential benefits and risks related to the use of these new insulins in pregnancy. Clinical and experimental data on insulin aspart and lispro strongly suggest that they have no adverse maternal or fetal effects during pregnancy in women with pregestational and gestational diabetes, and that their use results in improved glycemic control, fewer hypoglycemic episodes, and improved patient satisfaction. At present there are no published data on the use of glulisine in pregnancy. Insulin glargine during pregnancy is not recommended but, in the last years, larger surveys (retrospective and case–control studies) have been published on this field and, to date, results of about 335 pregnancies with type 1 diabetes are available showing an incidence of congenital malformation similar to that obtained with human insulin. There are no published data concerning the use of detemir in pregnancy but the results of a prospective study are expected in 2010.
- 16 June 2009
- Published by Springer Nature in Acta Diabetologica
- Vol. 46 (3) , 163-172
Insulin analogs and pregnancy: an update
It is well known that good metabolic control maintained throughout pregnancy reduces maternal and fetal complications in diabetes. Before conception and throughout pregnancy, insulin therapy needs to be optimized and, in this context, the insulin analogs currently available in the market may help to achieve good metabolic control. We therefore review here what is known about the potential benefits and risks related to the use of these new insulins in pregnancy. Clinical and experimental data on insulin aspart and lispro strongly suggest that they have no adverse maternal or fetal effects during pregnancy in women with pregestational and gestational diabetes, and that their use results in improved glycemic control, fewer hypoglycemic episodes, and improved patient satisfaction. At present there are no published data on the use of glulisine in pregnancy. Insulin glargine during pregnancy is not recommended but, in the last years, larger surveys (retrospective and case–control studies) have been published on this field and, to date, results of about 335 pregnancies with type 1 diabetes are available showing an incidence of congenital malformation similar to that obtained with human insulin. There are no published data concerning the use of detemir in pregnancy but the results of a prospective study are expected in 2010.